C4 Therapeutics, Inc.
Clinical trials sponsored by C4 Therapeutics, Inc., explained in plain language.
C4 Therapeutics, Inc.
CCCC
NASDAQ
A biotech company developing targeted protein degradation therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill shows promise for Tough-to-Treat blood cancers Results expected Sep 2026 (estimated) May already have reported ↗